Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US Securities and Exchange Commission (SEC) filing. The Californian biopharma ...
Aardvark Therapeutics filed for an IPO Thursday night, making it the sixth biotech in line this year for a potential listing … ...
Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...
In a 2025 punctuated by news from the weight-loss space, obesity-focused biotech Aardvark Therapeutics filed for an IPO Thursday, following competitor Metsera, which announced its own bid earlier this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback